Adding Ibrutinib to Chemoimmunotherapy Induction Improves FF

The addition of ibrutinib to chemoimmunotherapy induction with ASCT improved rates of failure-free survival in younger patients with mantle cell lymphoma.

Related Keywords

Germany , Munich , Bayern , Martin Dreyling , University Hospital Munich , International Prognostic Index , Department Of Internal Medicine , Prognostic Index , Internal Medicine , Hospital Munich , Ann Arbor ,